# Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

> **NCT02059291** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 203 (actual)

## Conditions studied

- Hereditary Periodic Fevers

## Interventions

- **DRUG:** Canakinumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02059291
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-27
- **Primary completion:** 2017-07-04
- **Final completion:** 2017-07-04
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2018-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02059291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02059291, "Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02059291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*